{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:43:59Z","timestamp":1792003439544,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.09.033","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T01:24:31Z","timestamp":1542417871000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"special_numbering":"C","title":["Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"106","author":[{"given":"Alvaro","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Knauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Mitzel-Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Martin","family":"Thoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"T\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2018.09.033_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CCO.0000000000000358","article-title":"A review of serious adverse effects under treatment with checkpoint inhibitors","volume":"29","author":"Heinzerling","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2018.09.033_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.ejca.2018.09.033_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.033_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2018.09.033_bib5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2018.09.033_bib6","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.033_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.033_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.033_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/1078155216635853","article-title":"Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma","volume":"23","author":"Dasanu","year":"2017","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2018.09.033_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2018.09.033_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"10124","key":"10.1016\/j.ejca.2018.09.033_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"11 Supplement","key":"10.1016\/j.ejca.2018.09.033_bib13","doi-asserted-by":"crossref","first-page":"A699","DOI":"10.1016\/S0735-1097(18)31240-3","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.033_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy","volume":"41","author":"Tajmir-Riahi","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2018.09.033_bib15","first-page":"794842","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ejca.2018.09.033_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.033_bib17","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Therapeut"},{"issue":"18","key":"10.1016\/j.ejca.2018.09.033_bib18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.033_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/CMR.0000000000000251","article-title":"Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma","volume":"26","author":"Mehta","year":"2016","journal-title":"Melanoma Res"},{"issue":"10105","key":"10.1016\/j.ejca.2018.09.033_bib20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.ejca.2018.09.033_bib21","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.09.033_bib22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.033_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: a case report and a literature review","volume":"387","author":"Bourgeois-Vionnet","year":"2018","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.033_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.ejca.2018.09.033_bib25","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1634\/theoncologist.2016-0170","article-title":"A case of nivolumab-induced myositis","volume":"21","author":"Fox","year":"2016","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.09.033_bib26","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1080\/10428194.2016.1265115","article-title":"Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine","volume":"58","author":"Saini","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.033_bib27","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J Thorac Oncol: Offi Publ Int Assoc Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.033_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pneumo.2017.08.012","article-title":"Unexpected adverse events of immunotherapies in non-small cell lung cancer: about 2 cases","volume":"73","author":"de Chabot","year":"2017","journal-title":"Rev Pneumol Clin"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.033_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2217\/imt-2017-0174","article-title":"Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer","volume":"10","author":"Badovinac","year":"2018","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.033_bib30","first-page":"282","article-title":"Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases","volume":"40","author":"Pushkarevskaya","year":"2017","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"6\u20137","key":"10.1016\/j.ejca.2018.09.033_bib31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","article-title":"[Orbital myositis associated with ipilimumab]","volume":"140","author":"Lecouflet","year":"2013","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.033_bib32","first-page":"424","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit (Amsterdam, Netherlands)"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.033_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/S0317167100007939","article-title":"Autoimmune inflammatory myopathy after treatment with ipilimumab","volume":"36","author":"Hunter","year":"2009","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.033_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.033_bib35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheum (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.033_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.033_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.033_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2018.09.033_bib39","first-page":"208","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","author":"Liewluck","year":"2017","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"27","key":"10.1016\/j.ejca.2018.09.033_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"issue":"50","key":"10.1016\/j.ejca.2018.09.033_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.033_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.033_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5692\/clinicalneurol.cn-000991","article-title":"A case of myasthenia gravis and myositis induced by nivolumab","volume":"57","author":"Konoeda","year":"2017","journal-title":"Rinsho shinkeigaku Clin Neurol"},{"key":"10.1016\/j.ejca.2018.09.033_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.033_bib45","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12991","article-title":"Case of respiratory discomfort due to myositis after administration of nivolumab","volume":"42","author":"Yoshioka","year":"2015","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.033_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.09.033_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.033_bib48","doi-asserted-by":"crossref","first-page":"C18","DOI":"10.12968\/hmed.2012.73.Sup2.C18","article-title":"Dermatomyositis","volume":"73","author":"Mahil","year":"2012","journal-title":"Br J Hosp Med (London, England: 2005)"},{"key":"10.1016\/j.ejca.2018.09.033_bib49","doi-asserted-by":"crossref","first-page":"857519","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.033_bib50","first-page":"127","article-title":"Inflammatory myopathies","volume":"113","author":"Atluri","year":"2016","journal-title":"Mo Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.033_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/PL00007850","article-title":"Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies","volume":"249","author":"Hengstman","year":"2002","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.033_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/ket279","article-title":"Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy","volume":"53","author":"Venalis","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.033_bib53","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.033_bib54","first-page":"208","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"230","key":"10.1016\/j.ejca.2018.09.033_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.033_bib56","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000464","article-title":"Granulomatous myositis induced by anti\u2013PD-1 monoclonal antibodies","volume":"5","author":"Uchio","year":"2018","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.033_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/BOR.0000000000000326","article-title":"Value of MRI in diagnostics and evaluation of myositis","volume":"28","author":"Pipitone","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ejca.2018.09.033_bib58","doi-asserted-by":"crossref","first-page":"1093858","DOI":"10.1155\/2017\/1093858","article-title":"A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis","volume":"2017","author":"Sakai","year":"2017","journal-title":"Case Rep Med"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.033_bib59","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2018.09.033_bib60","first-page":"1","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","author":"Chen","year":"2017","journal-title":"Clin Toxicol (Philadelphia, Pa)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T11:27:06Z","timestamp":1605439626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":60,"alternative-id":["S0959804918314035"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}